Reaction

Facial Paresis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,511 reports · 57 co-occurring drugs

As of the last recalculation, Facial Paresis appears in 3,511 FAERS reports alongside 57 co-occurring drug terms. The strongest observed disproportionality signal is ONABOTULINUMTOXINA (PRR 97.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Onabotulinumtoxina	936	97.7	98.9
Botulinum Toxin Type A	85	41.6	41.9
Doxepin Hydrochloride	19	9.0	9.0
Doxepin	15	8.8	8.8
Mesna Injection	11	7.9	7.9
Mesna	11	7.8	7.8
Ravulizumab	16	7.0	7.1
Granisetron Hydrochloride	12	6.8	6.8
Cefuroxime	12	6.2	6.2
Nebivolol	16	6.0	6.0
Mercaptopurine	17	5.8	5.8
Ropinirole	14	5.4	5.4
Levodopa	11	5.4	5.4
Amantadine	13	5.0	5.0
Tenofovir Disoproxil Fumarate Tablets	7	4.8	4.8
Labetalol	10	4.5	4.5
Rotigotine	10	4.1	4.1
Blinatumomab	7	4.0	4.0
Cytarabine	40	4.0	4.0
Brivaracetam	6	4.0	4.0
Vemurafenib	8	4.0	4.0
Lopinavir And Ritonavir	9	3.9	3.9
Valganciclovir Hydrochloride Powder,	8	3.9	3.9
Cetirizine Hcl	6	3.9	3.9
Pegaspargase	8	3.9	3.9
Nebivolol Hydrochloride	20	3.5	3.5
Drospirenone And Ethinyl Estradiol	26	3.5	3.5
Fingolimod Hcl	50	3.5	3.5
Dabigatran Etexilate	44	3.4	3.4
Temozolomide	12	3.4	3.4
Dabigatran Etexilate Mesylate	41	3.4	3.4
Vincristine Sulfate	16	3.2	3.2
Bupivacaine	5	3.2	3.2
Cyclophosphamide Injection, Solution	93	3.2	3.2
Cyclophosphamide	93	3.2	3.2
Cyclophosphamide For Injection	93	3.2	3.2
Ribavirin	33	3.1	3.1
Nilotinib	15	3.0	3.0
Doxorubicin	43	2.9	2.9
Granisetron	5	2.8	2.8
Ticagrelor	15	2.8	2.8
Bimatoprost	13	2.7	2.7
Agalsidase Beta	4	2.6	2.6
Ifosfamide	9	2.5	2.5
Peginterferon Alfa-2A	22	2.4	2.4
Eculizumab	22	2.4	2.4
Irinotecan Hydrochloride	5	2.3	2.3
Remdesivir	5	2.2	2.2
Ranitidine Hydrochloride	20	2.2	2.2
Ofatumumab	12	2.1	2.1
Sofosbuvir	7	2.1	2.1
Ocrelizumab	21	2.0	2.0
Canagliflozin	10	2.0	2.0
Eptinezumab-Jjmr	3	2.0	2.0
Encorafenib	3	1.8	1.8
Romosozumab-Aqqg	4	1.7	1.7
Valbenazine	3	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.